

Zwi N Berneman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6766100/publications.pdf>

Version: 2024-02-01

184
papers

7,997
citations

53794

45
h-index

60623

81
g-index

187
all docs

187
docs citations

187
times ranked

10321
citing authors

#	ARTICLE	IF	CITATIONS
1	Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner. <i>Cytotherapy</i> , 2022, , .	0.7	4
2	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. <i>Frontiers in Immunology</i> , 2022, 13, 734256.	4.8	2
3	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. <i>Journal of Translational Medicine</i> , 2022, 20, 124.	4.4	21
4	Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen-glucose Deprivation. <i>Neurotherapeutics</i> , 2022, 19, 550-569.	4.4	5
5	Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab624.	0.9	21
6	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Oncolmmunology</i> , 2022, 11, .	4.6	54
7	Functional consequences of a close encounter between microglia and brain-infiltrating monocytes during CNS pathology and repair. <i>Journal of Leukocyte Biology</i> , 2021, 110, 89-106.	3.3	6
8	Murine induced pluripotent stem cell-derived neuroimmune cell culture models emphasize opposite immune effector functions of interleukin 13-primed microglia and macrophages in terms of neuroimmune toxicity. <i>Glia</i> , 2021, 69, 326-345.	4.9	4
9	Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future. <i>Frontiers in Immunology</i> , 2021, 12, 624685.	4.8	15
10	The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. <i>Pharmaceutics</i> , 2021, 13, 396.	4.5	18
11	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. <i>European Journal of Cancer</i> , 2021, 148, 328-339.	2.8	14
12	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 213.	8.6	42
13	Transmigration across a Steady-State Blood-Brain Barrier Induces Activation of Circulating Dendritic Cells Partly Mediated by Actin Cytoskeletal Reorganization. <i>Membranes</i> , 2021, 11, 700.	3.0	6
14	Triple-negative breast cancer: Role of immunology: A systemic review. <i>Breast Journal</i> , 2020, 26, 995-999.	1.0	36
15	Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics. <i>Journal of Clinical Medicine</i> , 2020, 9, 3090.	2.4	8
16	The immunologic aspects in hormone receptor positive breast cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100207.	1.7	4
17	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 164.	17.0	88
18	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , 2020, 89, 102068.	7.7	60

#	ARTICLE	IF	CITATIONS
19	HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients. <i>Cells</i> , 2020, 9, 2703.	4.1	0
20	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. <i>Cancers</i> , 2020, 12, 256.	3.7	12
21	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready to Improve Clinical Outcome?. <i>Cancers</i> , 2020, 12, 299.	3.7	2
22	Neuroprotective modulation of microglia effector functions following priming with interleukin 4 and 13: current limitations in understanding their mode-of-action. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 856-866.	4.1	30
23	Mycosis fungoides of the vulva. <i>Åstanbul Kuzey Klinikleri</i> , 2020, 8, 101-105.	0.3	0
24	Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. <i>Journal of Neuroinflammation</i> , 2019, 16, 167.	7.2	20
25	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. <i>Frontiers in Immunology</i> , 2019, 10, 1613.	4.8	70
26	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. <i>Cancers</i> , 2019, 11, 1029.	3.7	7
27	Murine iPSC-derived microglia and macrophage cell culture models recapitulate distinct phenotypical and functional properties of classical and alternative neuro-immune polarisation. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 406-421.	4.1	19
28	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. <i>Cancers</i> , 2019, 11, 1396.	3.7	13
29	Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. <i>Acta Haematologica</i> , 2019, 142, 197-207.	1.4	6
30	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 579.	2.4	48
31	COMPARISON OF THE POWER OF PROCALCITONIN AND C-REACTIVE PROTEIN TO DISCRIMINATE BETWEEN DIFFERENT AETIOLOGIES OF FEVER IN PROLONGED PROFOUND NEUTROPENIA: A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019023.	1.3	7
32	Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 594-605.	3.4	5
33	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. <i>BMJ Open</i> , 2019, 9, e030309.	1.9	63
34	Bone marrow histology in CALR mutated thrombocythemia and myelofibrosis: results from two cross sectional studies in 70 newly diagnosed JAK2/MPL wild type thrombocythemia patients. , 2019, 2, 064-078.		0
35	To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 178-192.	1.7	42
36	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. <i>Oncolmmunology</i> , 2018, 7, e1407899.	4.6	38

#	ARTICLE	IF	CITATIONS
37	Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. <i>Frontiers in Immunology</i> , 2018, 9, 2503.	4.8	29
38	Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo CCR5 Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. <i>Frontiers in Immunology</i> , 2018, 8, 1964.	4.8	8
39	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. <i>Frontiers in Immunology</i> , 2018, 9, 658.	4.8	38
40	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. <i>Oncotarget</i> , 2018, 9, 27797-27808.	1.8	17
41	Immune remodelling of stromal cell grafts in the central nervous system: therapeutic inflammation or (harmless) side-effect?. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 2846-2852.	2.7	9
42	Concise Review: Innate and Adaptive Immune Recognition of Allogeneic and Xenogeneic Cell Transplants in the Central Nervous System. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1434-1441.	3.3	34
43	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. <i>Blood</i> , 2017, 130, 1713-1721.	1.4	170
44	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. <i>Cancer Immunology Research</i> , 2017, 5, 710-715.	3.4	36
45	Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions. <i>Experimental Hematology and Oncology</i> , 2017, 6, 9.	5.0	11
46	Increased Transendothelial Transport of CCL3 Is Insufficient to Drive Immune Cell Transmigration through the Blood-Brain Barrier under Inflammatory Conditions In Vitro. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	3.0	16
47	Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. <i>Oncotarget</i> , 2017, 8, 13652-13665.	1.8	18
48	Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens. <i>Journal of Immunology Research</i> , 2016, 2016, 1-16.	2.2	18
49	12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	3.0	46
50	GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use. <i>Methods in Molecular Biology</i> , 2016, 1428, 139-150.	0.9	12
51	The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?. <i>Molecular Therapy</i> , 2016, 24, 1896-1897.	8.2	0
52	Intracerebral transplantation of interleukin 13-producing mesenchymal stem cells limits microgliosis, oligodendrocyte loss and demyelination in the cuprizone mouse model. <i>Journal of Neuroinflammation</i> , 2016, 13, 288.	7.2	34
53	Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN- γ in patients with relapsing-remitting multiple sclerosis. <i>Innate Immunity</i> , 2016, 22, 266-273.	2.4	9
54	Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2016, 1393, 27-35.	0.9	6

#	ARTICLE	IF	CITATIONS
55	Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages. <i>Glia</i> , 2016, 64, 2181-2200.	4.9	53
56	In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell Implants. <i>Stem Cells</i> , 2016, 34, 1971-1984.	3.2	17
57	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. <i>Journal of Hematology and Oncology</i> , 2016, 9, 101.	17.0	96
58	Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 113.	7.2	42
59	CMRF-56 ⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncolmmunology</i> , 2016, 5, e1168555.	4.6	17
60	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. <i>Oncotarget</i> , 2016, 7, 73960-73970.	1.8	17
61	Optical Coherence Tomography in Cultivated Limbal Epithelial Stem Cell Transplantation Surgery. <i>Asia-Pacific Journal of Ophthalmology</i> , 2015, 4, 339-345.	2.5	17
62	Early Inflammatory Responses following Cell Grafting in the CNS Trigger Activation of the Subventricular Zone: A Proposed Model of Sequential Cellular Events. <i>Cell Transplantation</i> , 2015, 24, 1481-1492.	2.5	19
63	Distinct In Vitro Properties of Embryonic and Extraembryonic Fibroblast-Like Cells are Reflected in their in Vivo Behavior following Grafting in the Adult Mouse Brain. <i>Cell Transplantation</i> , 2015, 24, 223-233.	2.5	6
64	Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. <i>PLoS ONE</i> , 2015, 10, e0123340.	2.5	47
65	Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	8
66	Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra. <i>NMR in Biomedicine</i> , 2015, 28, 505-513.	2.8	20
67	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA-Transfected Dendritic Cells. <i>Transplantation</i> , 2015, 99, 120-127.	1.0	36
68	OP043D CULTURE OF MURINE NEURAL STEM CELLS ON DECELLULARIZED MOUSE BRAIN SECTIONS. <i>Neuro-Oncology</i> , 2015, 17, viii16.4-viii16.	1.2	1
69	Changing Concepts of Diagnostic Criteria of Myeloproliferative Disorders and the Molecular Etiology and Classification of Myeloproliferative Neoplasms: From Dameshek 1950 to Vainchenker 2005 and Beyond. <i>Acta Haematologica</i> , 2015, 133, 36-51.	1.4	39
70	Bone matrix vesicle-bound alkaline phosphatase for the assessment of peripheral blood admixture to human bone marrow aspirates. <i>Clinica Chimica Acta</i> , 2015, 446, 253-260.	1.1	6
71	Engineering monocyte-derived dendritic cells to secrete interferon- γ enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 831-842.	4.2	27
72	Aspirin-Responsive, Migraine-Like Transient Cerebral and Ocular Ischemic Attacks and Erythromelalgia in JAK2 ^{V617F} -Positive Essential Thrombocythemia and Polycythemia Vera. <i>Acta Haematologica</i> , 2015, 133, 56-63.	1.4	26

#	ARTICLE	IF	CITATIONS
73	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2015, 67, 731-753.	16.0	129
74	3D culture of murine neural stem cells on decellularized mouse brain sections. <i>Biomaterials</i> , 2015, 41, 122-131.	11.4	75
75	Transpresentation of interleukin-15 by IL-15/IL-15R α mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. <i>Oncotarget</i> , 2015, 6, 44123-44133.	1.8	39
76	Distinct spatial distribution of microglia and macrophages following mesenchymal stem cell implantation in mouse brain. <i>Immunology and Cell Biology</i> , 2014, 92, 650-658.	2.3	30
77	The European Clinical, Molecular, and Pathological (ECMP) Criteria and the 2007/2008 Revisions of the World Health Organization for the Diagnosis, Classification, and Staging of Prefibrotic Myeloproliferative Neoplasms Carrying the JAK2V617F Mutation. <i>Turkish Journal of Haematology</i> , 2014, 239-254.	0.5	5
78	Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. <i>European Journal of Haematology</i> , 2014, 93, 302-308.	2.2	25
79	Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. <i>Multiple Sclerosis Journal</i> , 2014, 20, 548-557.	3.0	31
80	Electroporating Human Corneal Epithelial Cells With Interleukin 10 and Fas Ligand pDNA. <i>Asia-Pacific Journal of Ophthalmology</i> , 2014, 3, 56-63.	2.5	0
81	Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. <i>Journal of Translational Medicine</i> , 2014, 12, 58.	4.4	96
82	Cellular and molecular neuropathology of the cuprizone mouse model: Clinical relevance for multiple sclerosis. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 47, 485-505.	6.1	352
83	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.	1.6	145
84	Except for C-C chemokine receptor 7 expression, monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls. <i>Cytotherapy</i> , 2014, 16, 1024-1030.	0.7	8
85	Clinical use of dendritic cells for cancer therapy. <i>Lancet Oncology</i> , The, 2014, 15, e257-e267.	10.7	565
86	Histological Characterization and Quantification of Cellular Events Following Neural and Fibroblast(-Like) Stem Cell Grafting in Healthy and Demyelinated CNS Tissue. <i>Methods in Molecular Biology</i> , 2014, 1213, 265-283.	0.9	7
87	Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients. <i>Blood</i> , 2014, 124, 310-310.	1.4	5
88	Quantitative and phenotypic analysis of mesenchymal stromal cell graft survival and recognition by microglia and astrocytes in mouse brain. <i>Immunobiology</i> , 2013, 218, 696-705.	1.9	37
89	mRNA Electroporation as a Tool for Immunomonitoring. <i>Methods in Molecular Biology</i> , 2013, 969, 293-303.	0.9	5
90	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	1.6	78

#	ARTICLE	IF	CITATIONS
91	Quantitative Evaluation of Stem Cell Grafting in the Central Nervous System of Mice by In Vivo Bioluminescence Imaging and Postmortem Multicolor Histological Analysis. <i>Methods in Molecular Biology</i> , 2013, 1052, 125-141.	0.9	6
92	Tackling the physiological barriers for successful mesenchymal stem cell transplantation into the central nervous system. <i>Stem Cell Research and Therapy</i> , 2013, 4, 101.	5.5	23
93	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1956-1961.	3.3	28
94	Interferon β may be back on track to treat acute myeloid leukemia. <i>OncolImmunology</i> , 2013, 2, e23619.	4.6	33
95	Dendritic Cells: Cellular Mediators for Immunological Tolerance. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	56
96	Injury-Dependent Retention of Intraportally Administered Mesenchymal Stromal Cells Following Partial Hepatectomy of Steatotic Liver Does Not Lead to Improved Liver Recovery. <i>PLoS ONE</i> , 2013, 8, e69092.	2.5	8
97	Neuroendocrine Immunoregulation in Multiple Sclerosis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-23.	3.3	46
98	Lymphangiogenesis May Play a Role in Cultivated Limbal Stem Cell Transplant Rejection. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 381-383.	1.8	3
99	Interleukin-12p70 Expression by Dendritic Cells of HIV-1-Infected Patients Fails to Stimulate gag-Specific Immune Responses. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	5
100	Optimizing Dendritic Cell-Based Immunotherapy: Tackling the Complexity of Different Arms of the Immune System. <i>Mediators of Inflammation</i> , 2012, 2012, 1-14.	3.0	42
101	NK Cells: Key to Success of DC-Based Cancer Vaccines?. <i>Oncologist</i> , 2012, 17, 1256-1270.	3.7	76
102	Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials. <i>Oncologist</i> , 2012, 17, 250-259.	3.7	75
103	Multimodal Imaging of Stem Cell Implantation in the Central Nervous System of Mice. <i>Journal of Visualized Experiments</i> , 2012, , e3906.	0.3	6
104	Cell Type-Associated Differences in Migration, Survival, and Immunogenicity following Grafting in CNS Tissue. <i>Cell Transplantation</i> , 2012, 21, 1867-1881.	2.5	36
105	mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. <i>Aids</i> , 2012, 26, F1-F12.	2.2	88
106	RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 1539-1547.	3.5	32
107	Autologous T cells on the attack against AML. <i>Blood</i> , 2012, 120, 1151-1152.	1.4	6
108	Dendritic cell vaccination in acute myeloid leukemia. <i>Cytotherapy</i> , 2012, 14, 647-656.	0.7	49

#	ARTICLE	IF	CITATIONS
109	Stem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?. <i>Regenerative Medicine</i> , 2012, 7, 245-259.	1.7	16
110	Spatiotemporal evolution of early innate immune responses triggered by neural stem cell grafting. <i>Stem Cell Research and Therapy</i> , 2012, 3, 56.	5.5	34
111	Human Tears Reveal Insights into Corneal Neovascularization. <i>PLoS ONE</i> , 2012, 7, e36451.	2.5	34
112	Current Challenges for the Advancement of Neural Stem Cell Biology and Transplantation Research. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 262-278.	5.6	75
113	Open label phase I/II study of Wilms' tumor gene 1 (WT1) mRNA-transfected autologous dendritic cell vaccination in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13051-e13051.	1.6	2
114	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. <i>PLoS ONE</i> , 2012, 7, e51851.	2.5	48
115	Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC. <i>PLoS ONE</i> , 2011, 6, e20952.	2.5	31
116	Clinical Potential of Intravenous Neural Stem Cell Delivery for Treatment of Neuroinflammatory Disease in Mice?. <i>Cell Transplantation</i> , 2011, 20, 851-870.	2.5	45
117	Labeling of Luciferase/eGFP-Expressing Bone Marrow-Derived Stromal Cells with Fluorescent Micron-Sized Iron Oxide Particles Improves Quantitative and Qualitative Multimodal Imaging of Cellular Grafts In Vivo. <i>Molecular Imaging and Biology</i> , 2011, 13, 1133-1145.	2.6	21
118	Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA. <i>Retrovirology</i> , 2011, 8, P76.	2.0	0
119	Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. <i>Immunotherapy</i> , 2011, 3, 1203-1222.	2.0	34
120	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. <i>Hum Vaccin</i> , 2011, 7, 579-584.	2.4	30
121	Recognition of cellular implants by the brain's innate immune system. <i>Immunology and Cell Biology</i> , 2011, 89, 511-516.	2.3	23
122	Role of Dendritic Cells in HIV-Immunotherapy. <i>Current HIV Research</i> , 2010, 8, 310-322.	0.5	17
123	The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 35-46.	4.2	51
124	The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. <i>Journal of Immunological Methods</i> , 2010, 357, 51-54.	1.4	12
125	Induction of complete remission of acute myeloid leukaemia by pegylated interferon- α 2a in a patient with transformed primary myelofibrosis. <i>British Journal of Haematology</i> , 2010, 149, 152-155.	2.5	27
126	Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13824-13829.	7.1	341

#	ARTICLE	IF	CITATIONS
127	Standardized Limbal Epithelial Stem Cell Graft Generation and Transplantation. <i>Tissue Engineering - Part C: Methods</i> , 2010, 16, 921-927.	2.1	54
128	Viral infections following allogeneic stem cell transplantation: how to cure the cure?. <i>Leukemia and Lymphoma</i> , 2010, 51, 965-966.	1.3	4
129	WT1-Targeted Dendritic Cell Vaccination as A Post-Remission Treatment to Prevent Full Relapse In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 16-16.	1.4	6
130	Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. <i>Anticancer Research</i> , 2010, 30, 3709-14.	1.1	20
131	Recessive von Willebrand Disease Type 2 Normandy: Variable Expression of Mild Hemophilia and VWD Type 1. <i>Acta Haematologica</i> , 2009, 121, 119-127.	1.4	7
132	Dominant von Willebrand Disease Type 2M and 2U Are Variable Expressions of One Distinct Disease Entity Caused by Loss-of-Function Mutations in the A1 Domain of the von Willebrand Factor Gene. <i>Acta Haematologica</i> , 2009, 121, 145-153.	1.4	16
133	Laboratory Diagnosis and Molecular Basis of Mild von Willebrand Disease Type 1. <i>Acta Haematologica</i> , 2009, 121, 85-97.	1.4	8
134	Managing Patients with von Willebrand Disease Type 1, 2 and 3 with Desmopressin and von Willebrand Factor-Factor VIII Concentrate in Surgical Settings. <i>Acta Haematologica</i> , 2009, 121, 167-176.	1.4	22
135	Immunotherapy of Acute Myeloid Leukemia: Current Approaches. <i>Oncologist</i> , 2009, 14, 240-252.	3.7	47
136	Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. <i>BMC Biotechnology</i> , 2009, 9, 1.	3.3	78
137	Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. <i>Immunology and Cell Biology</i> , 2009, 87, 267-273.	2.3	35
138	Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN- γ secretion by human NK cells. <i>Leukemia Research</i> , 2009, 33, 539-546.	0.8	11
139	Laboratory and Molecular Characteristics of Recessive von Willebrand Disease Type 2C (2A Subtype IIC) of Variable Severity due to Homozygous or Double Heterozygous Mutations in the D1 and D2 Domains. <i>Acta Haematologica</i> , 2009, 121, 111-118.	1.4	8
140	Dendritic Cell-Based Cancer Gene Therapy. <i>Human Gene Therapy</i> , 2009, 20, 1106-1118.	2.7	68
141	Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. <i>Journal of Translational Medicine</i> , 2009, 7, 109.	4.4	74
142	Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. <i>Cytotherapy</i> , 2009, 11, 653-668.	0.7	98
143	Laboratory Diagnosis of von Willebrand Disease Type 1/2E (2A Subtype IIE), Type 1 Vicenza and Mild Type 1 Caused by Mutations in the D3, D4, B1 and C1 Domains of the von Willebrand Factor Gene. <i>Acta Haematologica</i> , 2009, 121, 128-138.	1.4	21
144	Laboratory Diagnosis and Molecular Classification of von Willebrand Disease. <i>Acta Haematologica</i> , 2009, 121, 71-84.	1.4	41

#	ARTICLE	IF	CITATIONS
145	Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. <i>Blood</i> , 2009, 113, 5401-5411.	1.4	540
146	Cefepime and mortality. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 585-586.	9.1	1
147	The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy. <i>Oncologist</i> , 2008, 13, 859-875.	3.7	192
148	Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms's Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 830-830.	1.4	8
149	Immunotherapy of hematological malignancies using dendritic cells. <i>Bulletin Du Cancer</i> , 2008, 95, 320-6.	1.6	10
150	Regulatory T Cells and Human Disease. <i>Clinical and Developmental Immunology</i> , 2007, 2007, 1-10.	3.3	139
151	Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. <i>Molecular Immunology</i> , 2007, 44, 3222-3233.	2.2	59
152	Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1365-1374.	3.3	192
153	WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. <i>Leukemia Research</i> , 2007, 31, 1031-1038.	0.8	46
154	Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. <i>BMC Biotechnology</i> , 2007, 7, 90.	3.3	50
155	Expression and localization of CHODL ¹ E/CHODL ¹ E, the soluble isoform of chondrolectin. <i>Cell Biology International</i> , 2007, 31, 1323-1330.	3.0	5
156	Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms's Tumor Protein WT1: A Phase I/II Trial. <i>Blood</i> , 2007, 110, 158-158.	1.4	2
157	mRNA-based gene transfer as a tool for gene and cell therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2007, 9, 423-31.	2.8	61
158	Induction of HIV-specific T-cell responses by gag. <i>Retrovirology</i> , 2006, 3, S78.	2.0	0
159	Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 199-205.	1.4	26
160	Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. <i>Blood</i> , 2006, 107, 1818-1827.	1.4	56
161	Simultaneous Activation of Viral Antigen-specific Memory CD4+ and CD8+ T-cells Using mRNA-electroporated CD40-activated Autologous B-cells. <i>Journal of Immunotherapy</i> , 2006, 29, 512-523.	2.4	12
162	Cellular Immunotherapy for Cytomegalovirus and HIV-1 Infection. <i>Journal of Immunotherapy</i> , 2006, 29, 107-121.	2.4	10

#	ARTICLE	IF	CITATIONS
163	Gene expression signatures in CD34+progenitor-derived dendritic cells exposed to the chemical contact allergen nickel sulfate. <i>Toxicology and Applied Pharmacology</i> , 2006, 216, 131-149.	2.8	33
164	The Paradox of Platelet Activation and Impaired Function: Platelet-von Willebrand Factor Interactions, and the Etiology of Thrombotic and Hemorrhagic Manifestations in Essential Thrombocythemia and Polycythemia Vera. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 589-604.	2.7	139
165	Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 174-207.	2.7	94
166	The 2001 World Health Organization and Updated European Clinical and Pathological Criteria for the Diagnosis, Classification, and Staging of the Philadelphia Chromosome-Negative Chronic Myeloproliferative Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 307-340.	2.7	55
167	Guidelines for the Evaluation of Intravenous Desmopressin and von Willebrand Factor/Factor VIII Concentrate in the Treatment and Prophylaxis of Bleedings in von Willebrand Disease Types 1, 2, and 3. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 636-645.	2.7	10
168	Cytokine transcript profiling in CD34+progenitor derived dendritic cells exposed to contact allergens and irritants. <i>Toxicology Letters</i> , 2005, 155, 187-194.	0.8	26
169	Capacity of CD34+ progenitor-derived dendritic cells to distinguish between sensitizers and irritants. <i>Toxicology Letters</i> , 2005, 156, 377-389.	0.8	25
170	Activation of HIV-1-Specific CD8+ and CD4+ Autologous Memory T-Cells by Dendritic Cells and B-Cells Electroporated with mRNA Encoding Consensus or Autologous HIV-1 Proteins.. <i>Blood</i> , 2005, 106, 326-326.	1.4	0
171	Highly Efficient mRNA-Based Gene Transfer in Feeder-Free Cultured H9 Human Embryonic Stem Cells. <i>Cloning and Stem Cells</i> , 2004, 6, 211-216.	2.6	18
172	Immunotargetting of the Wilms's Tumor WT1 Antigen for Dendritic Cell and B-Cell-Based Vaccination of Leukemia.. <i>Blood</i> , 2004, 104, 2541-2541.	1.4	0
173	The Survival of Multiple Myeloma Patients: A Single Institution Study.. <i>Blood</i> , 2004, 104, 5223-5223.	1.4	0
174	RNA Electroporation as a New Gene Transfer Method in Hematopoietic Progenitor Cells, Mesenchymal Cells and Activated T-Cells.. <i>Blood</i> , 2004, 104, 5269-5269.	1.4	0
175	Efficient removal of LoxP-flanked genes by electroporation of Cre-recombinase mRNA. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 10-15.	2.1	17
176	Messenger RNA Electroporation of Human Monocytes, Followed by Rapid In Vitro Differentiation, Leads to Highly Stimulatory Antigen-Loaded Mature Dendritic Cells. <i>Journal of Immunology</i> , 2002, 169, 1669-1675.	0.8	56
177	Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2002, 28, 111-132.	2.7	50
178	Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. <i>Blood</i> , 2001, 98, 49-56.	1.4	438
179	Efficient generation of stably electrotransfected human hematopoietic cell lines without drug selection by consecutive FACsorting. <i>Cytometry</i> , 2000, 41, 31-35.	1.8	17
180	Enhancement of TAT-induced transactivation of the HIV-1 LTR by two genomic fragments of HHV-6. , 1996, 50, 20-24.		14

#	ARTICLE	IF	CITATIONS
181	Flow Cytometric Analysis of Erythrocytic Blood Group A Antigen Density Profile. Vox Sanguinis, 1991, 61, 265-274.	1.5	37
182	Flow cytometric analysis of hairy cell leukemia using right-angle light scatter. Cytometry, 1986, 7, 217-220.	1.8	13
183	Flow Cytometric Analysis of Erythrocytic D Antigen Density Profile. Vox Sanguinis, 1986, 51, 40-46.	1.5	34
184	Dendritic Cells in Hematopoietic Stem Cell Transplantation. , 0, , .		0